PT-141 | 10mg

$45.00

Cyclic melanocortin peptide (bremelanotide). MC3R/MC4R agonist acting centrally. FDA approved as Vyleesi. In vitro research use only.

Availability: 34 in stock

SKU: P41-ER Category:
Batch-Specific COA Included — View Sample

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from the hormone alpha-MSH, with a molecular weight of 1025.18 g/mol. Unlike PDE5 inhibitors, PT-141 works centrally, activating MC3R and MC4R receptors in the hypothalamus to modulate the neural circuits involved in sexual arousal, independent of vascular mechanisms.

Research has examined PT-141 in male and female models of sexual dysfunction, with clinical studies demonstrating receptor-mediated effects on desire and arousal pathways. Its central mechanism of action offers researchers a distinct pharmacological profile for studying the neural basis of sexual response in both sexes.

Each Etched Research vial contains 10mg of lyophilized powder, purity-verified at ≥99% via HPLC and mass spectrometry. Batch-specific Certificate of Analysis included.

Specifications:
– Molecular Formula: C50H68N14O10
– Molecular Weight: 1025.18 g/mol
– Purity: ≥99% (HPLC + Mass Spectrometry)
– Form: Lyophilized powder
– Storage: -20°C (lyophilized); 4°C once reconstituted, use within 30 days

FOR IN VITRO RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, INGESTION, OR ANY IN VIVO USE.

Research at a Glance
  • What it is: A synthetic peptide that switches on melanocortin receptors, a signaling system tied to sexual arousal. In the research literature it is called bremelanotide.
  • Researchers have studied it for: sexual desire and arousal (the main human trial literature) and melanocortin-pathway biology.
  • Evidence level: Real human evidence, but for one narrow use only. Two large phase 3 trials in premenopausal women, plus an FDA approval of a finished prescription drug for that single diagnosis. Outside that, the record is thin.
  • The short version: Bremelanotide is the most human-tested peptide in this catalog. In two large trials researchers watched it raise measured sexual-desire scores and lower related distress in premenopausal women, and regulators later approved a finished drug version for that one use. This page reports what researchers studied. It is not a recommendation to use the compound, and this material is supplied for research only.

Read the research →

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Scroll to Top